申请人:Xenon Pharmaceuticals Inc.
公开号:US20170114075A1
公开(公告)日:2017-04-27
This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.